Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 01/16/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CALT vs. VKTX, CRNX, ADMA, KRYS, TGTX, APLS, ACLX, SRRK, ALVO, and OGNShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), ADMA Biologics (ADMA), Krystal Biotech (KRYS), TG Therapeutics (TGTX), Apellis Pharmaceuticals (APLS), Arcellx (ACLX), Scholar Rock (SRRK), Alvotech (ALVO), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Viking Therapeutics Crinetics Pharmaceuticals ADMA Biologics Krystal Biotech TG Therapeutics Apellis Pharmaceuticals Arcellx Scholar Rock Alvotech Organon & Co. Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, community ranking, institutional ownership, dividends, analyst recommendations, risk and earnings. Which has stronger valuation and earnings, CALT or VKTX? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Viking TherapeuticsN/AN/A-$85.89M-$0.93-35.11 Do analysts recommend CALT or VKTX? Calliditas Therapeutics AB (publ) presently has a consensus target price of $39.25, indicating a potential downside of 1.88%. Viking Therapeutics has a consensus target price of $106.75, indicating a potential upside of 226.95%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Viking Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.15 Which has more volatility & risk, CALT or VKTX? Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Does the media favor CALT or VKTX? In the previous week, Viking Therapeutics had 10 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 10 mentions for Viking Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Viking Therapeutics' average media sentiment score of 0.33 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Viking Therapeutics Neutral Do institutionals and insiders believe in CALT or VKTX? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 4.7% of Viking Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer CALT or VKTX? Viking Therapeutics received 594 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Viking TherapeuticsOutperform Votes62179.92% Underperform Votes15620.08% Is CALT or VKTX more profitable? Viking Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Viking Therapeutics' return on equity of -12.73% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Viking Therapeutics N/A -12.73%-12.31% SummaryViking Therapeutics beats Calliditas Therapeutics AB (publ) on 14 of the 18 factors compared between the two stocks. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$6.58B$5.36B$9.14BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-21.629.8389.4717.33Price / Sales0.74305.831,262.70136.43Price / CashN/A61.4443.7535.97Price / Book37.746.055.324.80Net Income-$43.96M$154.62M$122.60M$224.91M7 Day PerformanceN/A-1.68%0.69%1.77%1 Month PerformanceN/A-2.35%1.55%2.22%1 Year Performance67.22%1.02%27.25%20.67% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180VKTXViking Therapeutics3.922 of 5 stars$42.58-0.7%$106.75+150.7%+52.4%$4.74BN/A-45.7820Analyst ForecastGap DownCRNXCrinetics Pharmaceuticals3.72 of 5 stars$50.48-5.0%$74.40+47.4%+1.5%$4.68B$1.04M-13.53210Short Interest ↑ADMAADMA Biologics3.9377 of 5 stars$19.08+3.5%$21.25+11.4%+224.9%$4.51B$382.81M68.14530Short Interest ↑Analyst RevisionPositive NewsGap DownKRYSKrystal Biotech4.8312 of 5 stars$156.74-1.0%$206.67+31.9%+17.8%$4.51B$241.52M88.55229Short Interest ↓TGTXTG Therapeutics4.4921 of 5 stars$28.07-6.6%$40.67+44.9%+93.1%$4.37B$264.79M-280.67290Analyst ForecastAnalyst RevisionNews CoverageAPLSApellis Pharmaceuticals4.4045 of 5 stars$34.28+2.5%$49.94+45.7%-54.6%$4.26B$715.22M-16.89702Analyst ForecastInsider TradeShort Interest ↑Gap UpACLXArcellx3.1778 of 5 stars$75.36-4.8%$105.93+40.6%+21.2%$4.08B$155.82M-106.14130Short Interest ↑SRRKScholar Rock3.1277 of 5 stars$43.01-4.8%$40.43-6.0%+176.7%$4.03B$33.19M-18.30140Positive NewsALVOAlvotech2.552 of 5 stars$13.33+0.5%$18.00+35.0%+7.4%$4.02B$391.87M-7.211,026Positive NewsOGNOrganon & Co.4.8105 of 5 stars$15.41-0.2%$21.33+38.4%-0.8%$3.97B$6.41B3.0610,000Positive News Related Companies and Tools Related Companies Viking Therapeutics Alternatives Crinetics Pharmaceuticals Alternatives ADMA Biologics Alternatives Krystal Biotech Alternatives TG Therapeutics Alternatives Apellis Pharmaceuticals Alternatives Arcellx Alternatives Scholar Rock Alternatives Alvotech Alternatives Organon & Co. Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CALT) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
